

DAFTAR PUSTAKA

1. American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.
2. Hutauruk T, Palealu O, Palandeng OI. Tumor kepala leher di poliklinik THT-KL RSUP Prof. Dr. R. D. Kandou Manado periode Januari 2010-Desember 2012. *Jurnal e-Clinic (ECL)*. 2013;1(2):1-9.
3. Adham M, Kurniawan AN, Muhtadi AI, Roezin A, Hermani B, Gondhowiardjo S, et al. Nasopharyngeal carcinoma in Indonesia: Epidemiology, incidence, signs, and symptoms at presentation. *Chinese Journal of Cancer*. 2012;31(4):185-96.
4. Roezin A, Adham M. Karsinoma nasofaring. In: Soepardi EA, Iskandar N, Bashiruddin J, Restuti RD, editors. *Buku ajar ilmu kesehatan telinga hidung tenggorok kepala dan leher*. 7th ed. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia; 2017. p156-7.
5. Global Cancer Observatory. Nasopharynx Fact Sheet [Internet]. 2020. Diakses melalui: <https://gco.iarc.fr/today/data/factsheets/cancers/4-Nasopharynx-fact-sheet.pdf> - Diakses April 2021.
6. Global Cancer Observatory. Indonesia Cancer Fact Sheet [Internet]. 2020. Diakses melalui: <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf> - Diakses April 2021.
7. Sabirin MSM, Permana AD, Soeseno B. Epidemiologi penderita tumor ganas kepala leher di departemen telinga hidung tenggorokan-kepala leher Rumah Sakit Dr. Hasan Sadikin Bandung, Indonesia, periode 2010-2014. *Tunas Medika Jurnal Kedokteran dan Kesehatan*. 2016;3(1):1-6.
8. Faiza S, Rahman S, Asri A. Karakteristik klinis dan patologis karsinoma nasofaring di bagian THT-KL RSUP Dr. M. Djamil Padang. *Jurnal Kesehatan Andalas*. 2016;5(1):90-6.
9. Komite Penanggulangan Kanker Nasional Kementerian Kesehatan Republik Indonesia. *Pedoman nasional pelayanan kedokteran kanker nasofaring*. 2017.
10. Kentjono WA. Perkembangan terkini penatalaksanaan karsinoma nasofaring. *Majalah Kedokteran Tropis Indonesia*. 2003;14(2):1-39.
11. National Comprehensive Cancer Network. *NCCN clinical practice guidelines in oncology (NCCN guidelines) head and neck cancers version 1.2021*. 2021.
12. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. *The Lancet*. 2019;394(10192):64-80.

13. Lee AWM, Ma BBY, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma: Current practice and future perspective. *Journal of Clinical Oncology*. 2015;33(29):3356-64.
14. Yoshizaki T, Ito M, Muro S, Wakisaka N, Kondo S, Endo K. Current understanding and management of nasopharyngeal carcinoma. *Auris Nasus Larynx*. 2012;39(2):137-44.
15. Paiar F, Cataldo VD, Zei G, Pasquetti EM, Cecchini S, Meattini I, et al. Role of chemotherapy in nasopharyngeal carcinoma. *Oncology Reviews*. 2012;6(1):1-6.
16. Perri F, Scarpati GDV, Caponigro F, Ionna F, Longo F, Buonopane S, et al. Management of recurrent nasopharyngeal carcinoma: Current perspectives. *Onco Targets and Therapy*. 2019;12:1583-91.
17. Chan JYW. Surgical management of recurrent nasopharyngeal carcinoma. *Oral Oncology*. 2014;50(10):913-7.
18. Mustajabah L, Setiawan D, Sudarso. Pola terapi pada pasien kanker nasofaring di RSUD Prof. Dr. Margono Soekarjo. *Journal Pharmacy of Indonesia*. 2012;9(2):94-117.
19. Dewi IK. Karakteristik dan jenis terapi pasien karsinoma nasofaring di bagian radioterapi RSUP Dr. Hasan Sadikin Bandung periode Januari-Desember 2015 [Skripsi]. Universitas Jenderal Achmad Yani; 2017.
20. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *European Journal of Cancer*. 2009;45(2):228-47.
21. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: Review of traditional and new criteria. *Radiographics*. 2013;33(5):1323-41.
22. Rahajeng N, Gondhowiardjo S, Musa Z. Respon radiasi dan kesintasan karsinoma nasofaring stadium lanjut lokal di Departemen Radioterapi Rumah Sakit Cipto Mangunkusumo periode Januari 2007-Desember 2011. *Radioterapi dan Onkologi Indonesia*. 2015;6(2):50-6.
23. Wildeman MA, Fles R, Herdini C, Indrasari RS, Vincent AD, Tjokronagoro M, et al. Primary treatment results of nasopharyngeal carcinoma (NPC) in Yogyakarta, Indonesia. *PLOS ONE*. 2013;8(5):1-6.
24. Regauer S. Nasopharynx and waldeyer's ring. In: Cardesa A, Sliotweg PJ, editors. *Pathology of the head and neck*. Germany: Springer; 2006. p173-82.
25. Faisal HH. Gambaran karakteristik karsinoma nasofaring dan faktor-faktor yang mempengaruhi prognosis. *Jurnal Universitas Indonesia*. 2016:1-24.

26. Mankwoski NL, Bordoni B. Anatomy, head and neck, nasopharynx [Internet]. Treasure Island: Statpearls Publishing; 2021. Diakses melalui: <https://www.statpearls.com/ArticleLibrary/viewarticle/32282> - Diakses Maret 2021.
27. Snell RS. Anatomi klinik untuk mahasiswa kedokteran. 6th ed. Jakarta: EGC; 2006. p796-9.
28. Wei WI, Chua DT. Pharynx: nasopharynx. In: Watkinson JC, Gilbert RW, editors. Stell and Maran's textbook of head and neck surgery and oncology. 5th ed. London: Hodder Arnold; 2012. p588-96.
29. Lee N, Chan K. Benign and malignant lesions of the oral cavity, oropharynx, and nasopharynx. In: Lalwani AK, editor. Current diagnosis and treatment in otolaryngology head and neck surgery. 2nd ed. United States of America: The McGraw-Hill Companies, Inc; 2008. p362-3.
30. Chong VFH. Neoplasms of the nasopharynx. In: Hermans R, editor. Head and neck cancer imaging. 1st ed. Germany: Springer; 2006. p149-50.
31. Khoo ASB, Pua KC. Diagnosis and clinical evaluation of nasopharyngeal carcinoma. In: Busson P, editor. Nasopharyngeal carcinoma: Keys for translational medicine and biology. 1st ed. New York: Springer Science and Business Media; 2013. p1-9.
32. Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavi N. Nasopharyngeal cancer in the world: Epidemiology, incidence, mortality and risk factors. World Cancer Research Journal. 2018;5(1):1-8.
33. Linton RE, Daker M, Khoo ASB, Choo DCY, Viljoen M, Neilsen PM. Nasopharyngeal carcinoma among the Bidayuh of Sarawak, Malaysia: History and risk factors (Review). Oncology Letters. 2021;22(1):1-8.
34. Handayani R, Dewi YA, Madani DZ. Prevalence of nasopharyngeal carcinoma patients in the Department of ORL-HNS Hasan Sadikin General Hospital 2010-2017. International Journal of Nasopharyngeal Carcinoma. 2020;2(1):1-3.
35. Zeng MS, Zeng YX. Pathogenesis and etiology of nasopharyngeal carcinoma. In: Lu JJ, Cooper JS, Lee AWM, editors. Nasopharyngeal cancer multidisciplinary management. 1st ed. Germany: Springer; 2010. p9-25.
36. Tsang CM, Tsao SW. The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virologica Sinica. 2015;30(2):107-21.

37. Xie SH, Yu ITS, Tse LA, Mang OWK, Yue L. Sex difference in the incidence of nasopharyngeal carcinoma in Hong Kong 1983-2008: Suggestion of a potential protective role of oestrogen. *European Journal of Cancer*. 2013;49(1):150-5.
38. Hsu WL, Chien YC, Huang YT, Yu KJ, Ko JY, Lin CY, et al. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis. *Cancer Medicine*. 2020;9(5):1867-76.
39. Rahman S, Budiman BJ, Subroto H. Faktor risiko non-viral pada karsinoma nasofaring. *Jurnal Kesehatan Andalas*. 2015;4(3):988-95.
40. Nasution II, Lutan R, Munir D, Hafni, Wahyuni AS. Relationship between cigarette smoking and nasopharyngeal carcinoma. *International Journal of Nasopharyngeal Carcinoma*. 2019;1(1):17-23.
41. Rizal NI, Utama DS. Role of dietary intake as risk factor for nasopharyngeal carcinoma in Muhammadiyah Hospital Palembang June 2017-September 2018. *International Journal of Nasopharyngeal Carcinoma*. 2019;1(3):105-6.
42. Chan ATC, Teo PML, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. *Seminars in Oncology*. 2004;31(6):794-801.
43. Adham M, Lazim NM, Carlos R. Clinical presentation of nasopharyngeal carcinoma. In: Abdullah B, Balasubramanian A, Lazim NM, editors. *An evidence-based approach to the management of nasopharyngeal cancer*. 1st ed. United States of America: Academic Press; 2020. p93-109.
44. Wei WI, Kwong DLW. Current management strategy of nasopharyngeal carcinoma. *Clinical and Experimental Otorhinolaryngology*. 2010;3(1):1-12.
45. Pastor M, Pousa AL, Barco ED, Segura PP, Astorga BG, Castelo B, et al. SEOM clinical guideline in nasopharynx cancer (2017). *Clinical and Translational Oncology*. 2018;20(1):84-8.
46. Chan JKC, Slootweg PJ. Tumours of the nasopharynx. In: El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ, editors. *WHO classification of head and neck tumours*. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p67-9.
47. Thompson LDR. Update on nasopharyngeal carcinoma. *Head and Neck Pathology*. 2007;1(1):81-6.
48. Cho KJ, Jeong SU, Kim SB, Lee SW, Choi SH, Nam SY, et al. Basaloid squamous cell carcinoma of the head and neck: Subclassification into basal, ductal, and mixed subtypes based on comparison of clinico-

pathologic features and expression of p53, cyclin D1, epidermal growth factor receptor, p16, and human papillomavirus. *Journal of Pathology and Translational Medicine*. 2017;51(4):374-80.

49. Roy C, Choudhury KB, Basu S. Basaloid squamous cell carcinoma of nasopharynx: An extremely rare variety of tumour of nasopharynx. *Journal of the Indian Medical Association*. 2011;109(5):343-4.
50. American Joint Committee on Cancer. *AJCC cancer staging manual*. 8th ed. Chicago: American College of Surgeons; 2018. p107-8.
51. Stevenson MM. Nasopharyngeal cancer treatment protocols [Internet]. 2019. Diakses melalui: <https://emedicine.medscape.com/article/2047748-overview> - Diakses Mei 2021.
52. World Health Organization. *WHO handbook for reporting results of cancer treatment*. Geneva: WHO Offset Publication; 1979. p22-4.
53. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Bodén K, Eriksson-Alm Y, et al. Radiologic measurement of tumor response to treatment: Practical approaches and limitations. *Radiographics*. 2008;28(2):329-44.
54. Chalian H, Töre HG, Horowitz JM, Salem R, Miller FH, Yaghmai V. Radiologic assessment of response to therapy: Comparison of RECIST versions 1.1 and 1.0. *Radiographics*. 2011;31(7):2093-105.
55. Cancer Research UK. *Head and neck cancers incidence statistics* [Internet]. 2020. Diakses melalui: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers/incidence> - Diakses Juni 2021.
56. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiology, Biomarkers & Prevention*. 2021;30(6):1035-47.
57. Astang A. Karakteristik penderita karsinoma nasofaring pada pasien rawat jalan di Rumah Sakit Umum Pusat Dr. Wahidin Sudirohusodo periode Juni 2016-Juni 2017 [Skripsi]. Universitas Hasanuddin; 2017.
58. Maubere F, Nuaba IGA. Karakteristik pasien karsinoma nasofaring di poliklinik telinga hidung tenggorokan-kepala leher Rumah Sakit Umum Pusat Sanglah Denpasar pada bulan November-Desember 2014. *E-Jurnal Medika Udayana*. 2015;4(5):1-18.
59. Soraya H, Triwulandari E. Association of educational level and alcohol consumption in patients with nasopharyngeal carcinoma in dental clinic RSCM Jakarta between 2006-2009. *Jurnal Universitas Indonesia*. 2013:1-16.

60. Bangun HA, Simanjuntak AM. Karakteristik penderita kanker nasofaring di RSUD Dr. Pirngadi Medan tahun 2018. *Wahana Inovasi*. 2018;7(2):1-5.
61. Fles R, Bos ACRK, Supriyati, Rachmawati D, Waliyanti E, Tan IB, et al. The role of Indonesian patients' health behaviors in delaying the diagnosis of nasopharyngeal carcinoma. *BMC Public Health*. 2017;17(1):510.
62. Suta PDD, Saputra KAD, Sutanegara SWD. Profil penderita kanker nasofaring di Rumah Sakit Umum Pusat Sanglah Denpasar periode Januari-Desember tahun 2014. *E-Jurnal Medika*. 2019;8(2):1-14.
63. Unsal AA, Booth JR, Rossi NA, Byrd JK, Kountakis SE. Basaloid nasopharyngeal carcinoma: A population-based analysis of a rare tumor. *Laryngoscope*. 2019;129(12):2727-32.
64. Kanno M, Narita N, Fujimoto Y, Wakisaka N, Yoshizaki T, Kodaira T, et al. Third epidemiological analysis of nasopharyngeal carcinoma in the Central Region of Japan from 2006 to 2015. *Cancers*. 2019;11(8):1-12.
65. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma. *American Journal of Clinical Oncology*. 2002;25(3):219-23.
66. Wang Q, Xu G, Xia Y, Zuo J, Zeng G, Xue Z, et al. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma. *Oral Oncology*. 2020;111(104925):1-9.
67. Zeng Q, Wang J, Lv X, Li J, Yin LJ, Xiang YQ, et al. Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: finding from a propensity-matched analysis. *BMC Cancer*. 2016;16(693):1-10.
68. Lin JC. Adjuvant chemotherapy in advanced nasopharyngeal carcinoma based on plasma EBV load. *Journal of Radiation Oncology*. 2012;1(2):117-27.
69. Xu T, Shen C, Ou X, He X, Ying H, Hu C. The role of adjuvant chemotherapy in nasopharyngeal carcinoma with bulky neck lymph nodes in the era of IMRT. *Oncotarget*. 2016;7(15):21013-22.
70. Santoso BS, Surarso B, Ketjono WA. Radioterapi pada karsinoma nasofaring. *Jurnal THT-KL*. 2009;2(3):134-41.
71. Permana AD. Perbandingan respons tumor primer terhadap terapi radiasi antara karsinoma nasofaring WHO tipe III yang disertai ekspresi LMP-1 dan tanpa ekspresi LMP-1 [Tesis]. Universitas Padjajaran Bandung; 2008.

72. Satya N, Suwitodihardjo S. Treatment response and acute toxicity evaluation of 70 gray radiation in nasopharyngeal carcinoma patients in Dr. Soetomo Hospital Surabaya. *Folia Medica Indonesiana*. 2008;44(2):98-101.
73. Fibrian KC. Hubungan antara klasifikasi histopatologis dengan respon kemoradiasi berdasarkan gambaran CT Scan pada penderita karsinoma nasofaring [Skripsi]. Universitas Diponegoro; 2010.
74. Kim K, Wu HG, Kim HJ, Sung MW, Kim KH, Lee SH, et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma. *Head and Neck*. 2009;31(9):1121-8.
75. Kamer S, Esassolak M, Yalman D, Karabulut B, Bolukbasi Y, Aydin B. Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned?. *Medical Oncology*. 2008;25(1):93-9.
76. Chen PC, Liu WS, Huang WL, Wu CJ, Yang CC, Lee CC. The impact of time factors on overall survival in patients with nasopharyngeal carcinoma: A population-based study. *Radiation Oncology*. 2016;11(62):1-7.
77. Jones GDD, Symonds P. Molecular, cellular, and tissue effects of radiotherapy. In: Symonds P, Mills JA, Duxbury A, editors. *Walter and Miller's textbook of radiotherapy: Radiation physics, therapy and oncology*. 8th ed. China: Elsevier; 2019. p253-9.
78. Marliyawati D, Antono D, Yusmawan W. Respon neoadjuvant chemotherapy platinum based pada penderita karsinoma nasofaring di RSUP Dr. Kariadi Semarang. *Oto Rhino Laryngologica Indonesiana*. 2013;43(2):101-9.
79. Varlotto J, Stevenson MA. Anemia, tumor hypoxemia, and the cancer patient. *International Journal of Radiation Oncology, Biology, Physics*. 2005;63(1):25-36.
80. Du C, Ying H, Zhou J, Hu C, Zhang Y. Experience with combination of docetaxel, cisplatin plus 5-fluorouracil chemotherapy, and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma. *International Journal of Clinical Oncology*. 2013;18(3):464-71.